Inherent Targeting, LLC

Inherent Targeting, LLC is a for-profit limited liability company registered in SAM.gov since March 2022, with registration valid through October 2024. The company appears to be a biotechnology research firm specializing in developing advanced fluorescence imaging technologies for medical applications, with a particular focus on nerve tissue visualization and surgical guidance. Their primary work involves developing near-infrared fluorophores that can help surgeons more precisely identify and preserve nerve tissues during complex surgical procedures.

The company has secured multiple federal grant awards from prestigious scientific agencies, including the National Institute of Neurological Disorders and Stroke, National Cancer Institute, and National Science Foundation's Division of Industrial Innovation. These grants, totaling several hundred thousand dollars, have supported research into developing nerve-specific fluorophores for various surgical applications. Specifically, their grant-funded projects have included developing fluorescence imaging technologies for intraoperative nerve damage assessment in orthopaedic trauma surgery, creating near-infrared nerve-specific fluorophores for fluorescence-guided surgery, and developing clinical translation strategies for nerve-sparing prostatectomy. The research aims to improve surgical outcomes by providing surgeons with advanced visualization techniques that can help prevent nerve damage during complex medical procedures. Each grant represents a phase of technological development, with the ultimate goal of creating a robust diagnostic and surgical guidance platform that can be applied across multiple medical specialties.